- R&D 2H22 $USD 62 MN
- SG&A 2H22 $USD 8 MN (ex the $USD 7 MN one-time financing costs for Carlyle and for the equity raise in August/September 2022)
=> Cash YE22: $USD 142 MN
- R&D 1H23 $USD 62 MN
- SG&A 1H23 $USD 8 MN
+ R&D tax credit $USD 5 MN
=> Cash end of June 2023: $ 77 MN
- R&D 2H23 $USD 62 MN
- SG&A 2H23 $USD 8 MN
+ Second tranche DFA $35 MN
=> Cash YE23: $USD 42 MN
- R&D 1H24 $USD 62 MN
- SG&A 1H24 $USD 8 MN
+ R&D tax credit $USD 15 MN
+ Optional tranche DFA $USD 50 MN
=> Cash end of June 2024: $USD 37 MN
- R&D 3Q24 $USD 31 MN
- SG&A 3Q24 $USD 4 MN
=> Cash end of September 2024: $USD 2 MN. Game over.
That’s why I say „financed through mid 2024 only“. Of course, everybody is free to put different numbers at work.
Ann: Opthea Presents at the Jefferies 2023 Healthcare Conference, page-22
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
0.010(2.27%) |
Mkt cap ! $553.9M | |||
| Open | High | Low | Value | Volume |
| 44.0¢ | 45.5¢ | 43.5¢ | $417.7K | 934.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9400 | 44.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.5¢ | 26000 | 1 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| OPT (ASX) Chart |